All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
More information on our cookie policy.
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Artificial intelligence
Coronavirus
Diagnosing and tracking COVID-19
Drugs to Watch 2020
The next pandemic
Premium reports
BioWorld Financings Reports
Disease Forecast Reports
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 14, 2021
Home
» European Commission approves Pemazyre for cholangiocarcinoma with FGFR2 fusion or rearrangement
European Commission approves Pemazyre for cholangiocarcinoma with FGFR2 fusion or rearrangement
March 30, 2021
No Comments
Article reprints
Source:
https://science.bioworld.com/ddn/article.do?id=177278
BioWorld Science
Related Articles
Japanese MHLW approves Pemazyre for unresectable biliary tract cancer with FGFR2 fusion gene
